In combination with the results of previous studies and the present study, the KEAP1/NFE2L2 mutation, as a poor prognostic factor for NSCLC, is associated with poor prognosis with targeted therapy (26), chemotherapy (2–5), or immunotherapy (6–11). This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.